Kairos Pharma, LTD. 8-K

What Happened

• On February 26, 2026, Kairos Pharma, Ltd. (KAPA) announced it entered into a letter of intent (term sheet) with privately held Celyn Therapeutics, Inc. to acquire certain proprietary cancer-targeting small-molecule drugs.
• Under the LOI, Kairos will have the right to acquire worldwide rights to two clinical-stage oncology assets targeting non-small cell lung cancer (NSCLC): CL-273 (pre-IND, a reversible, wild-type-sparing pan-EGFR inhibitor) and CL-741 (Phase 1–ready, orally available type IIb c‑MET kinase inhibitor).
• The company furnished the press release announcing the LOI as Exhibit 99.1 to its Form 8‑K filed February 26, 2026.

Key Details

• Date filed: February 26, 2026 (Form 8‑K Item 8.01).
• Assets: CL-273 (pre-IND, pan-EGFR) and CL-741 (Phase 1–ready, oral c‑MET inhibitor).
• Scope: Right to acquire worldwide rights to both assets; Celyn Therapeutics is a private biotech.
• Disclosure: The filing discloses the LOI/term sheet but does not disclose purchase price, definitive agreement, or timing.

Why It Matters

• If completed, the transaction would add two clinical-stage oncology candidates to Kairos’s pipeline and expand its focus into NSCLC-targeted small molecules.
• For investors, this is a pipeline-expansion event; material outcomes (value impact, development timelines, costs, and final ownership) depend on any future definitive agreement, financial terms, and subsequent clinical progress—none of which were disclosed in the 8‑K.